This article presents a practical overview of the treatment of younger, newly diagnosed multiple myeloma patients, focusing on novel treatment strategies. With the introduction of effective new agents, multiple myeloma is one of the most active and changing fields in clinical oncology. In addition, monitoring technology has become reliable and practical. Achieving and sustaining minimal residual disease negativity (MRD- ), such as multiparameter flow cytometry (MFC) < 10-5, is one of the goals of therapy. MRD-  is significantly associated with prolonged progression-free survival, whereas MRD persistence (MRD +) is an independent factor for poor progression-free survival. Evidence from several recent studies evaluating modern therapy has further supported the positive correlation between depth of response and outcomes. Multiple myeloma can become a chronic illness with sustained MRD- in a significant number of patients. Our ultimate hope is to leverage tumoricidal-immunomodulatory sequential therapies and to cure a subset of our patients.

中文翻译：

---

旨在治愈可移植的多发性骨髓瘤患者的最新治疗策略：我如何以较低的费用治愈年轻的MM患者。

本文提供了一种新颖，更年轻的新诊断多发性骨髓瘤患者治疗的实用概述，重点是新颖的治疗策略。随着有效新型药物的引入，多发性骨髓瘤已成为临床肿瘤学中最活跃和变化最快的领域之一。另外，监视技术已经变得可靠和实用。实现和维持最小残留疾病阴性（MRD-），例如多参数流式细胞术（MFC）<10-5，是治疗的目标之一。MRD-与延长的无进展生存期显着相关，而MRD持续性（MRD +）是无进展生存期较差的独立因素。最近几项评估现代疗法的研究的证据进一步支持了反应深度与预后之间的正相关。在许多患者中，多发性骨髓瘤可成为持续MRD-的慢性疾病。我们的最终希望是利用肿瘤免疫调节序贯疗法并治愈部分患者。